In-Silico PK for PMTA: Running a 500-Subject Monte Carlo Virtual Trial

Answers: “in-silico PK model for PMTA / virtual clinical trial Monte Carlo nicotine PK”

A clinical PK study answers how nicotine from your product is absorbed and cleared — but it costs months and significant budget. An in-silico PK trial estimates the same core parameters computationally, before you commit.

How the virtual trial works

• A Monte Carlo simulation over a 500-subject cohort generates a distribution, not a single point estimate.
• Outputs: Cmax, Tmax and AUC₀–∞ with a 5–95% prediction interval (example values from the tool: Cmax 16.8 ng/mL, Tmax 13.5 min, AUC 762).
• Covariates include CYP2A6 metabolizer phenotype and body weight — the main physiological drivers of nicotine PK variability.
• Diagnostics follow a VPC (visual predictive check) style; no fabricated subject data is inserted.

The population-PK backbone draws on well-established nicotine pharmacokinetics literature (Benowitz, Hukkanen & Jacob, 2009).

Pros vs. cons. Pro: a 90% bootstrap CI and prediction intervals give reviewers a defensible uncertainty range in minutes, at a fixed price, with data staying in your browser. Con: a virtual trial is a model — it informs screening and supports a submission, but does not on its own substitute for the confirmatory clinical PK data FDA generally expects.

Who should NOT buy: teams with completed in-vivo PK datasets for the exact formulation and no need to screen alternatives.